Simcere Zaiming, Inc. - 31 Dec 2025 SCHEDULE 13G/A Report for NextCure, Inc. Common Stock, par value $0.001 per share (NXTC)

Key filing fact

Simcere Zaiming, Inc. disclosed 9.4% ownership in NextCure, Inc. Common Stock, par value $0.001 per share (NXTC) on 31 Dec 2025.

Key facts

Simcere Zaiming, Inc. filed SCHEDULE 13G/A for NextCure, Inc. Common Stock, par value $0.001 per share (NXTC).
Disclosed ownership: 9.4%.
Date of event: 31 Dec 2025.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Reporting persons

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title
Simcere Zaiming, Inc.	9.4%	338,636	338,636	0	/s/ Renhong Tang	Renhong Tang/Chief Executive Officer
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.	9.4%	338,636	338,636	0	/s/ Renhong Tang	Renhong Tang/Director and Attorney-in-Fact
Simcere Zaiming Pharmaceutical Co., Ltd.	9.4%	338,636	338,636	0	/s/ Renhong Tang	Renhong Tang/Chief Executive Officer and Chairman of the Board of Directors
Simcere Pharmaceutical Group Limited	9.4%	338,636	338,636	0	/s/ Jinsheng Ren	Jinsheng Ren/Chairman and Executive Director
Ren Jinsheng	9.4%	338,636	0	338,636	/s/ Jinsheng Ren	Jinsheng Ren
Tang Renhong	9.4%	338,636	0	338,636	/s/ Renhong Tang	Renhong Tang

CIK / CUSIP context first

Broader feeds